Skip to main content

Table 5 Summary of induction chemotherapy followed by (chemo)-radiotherapy

From: A single centre experience with sequential and concomitant chemoradiotherapy in locally advanced stage IV tonsillar cancer

  Leeds RMH, UK (19) Posner et al (15) Hitt et al (16) Vokes et al (20) Machtay et al (21) Urba et al (22)
Sequential theapy (IC + CRT) IC: PF 1-4 cycles
CRT (70 Gy in 35# Cisplatin100 m g/m2 day 1, 22, 43)/55 gy in20# Cisplatin day 1, 28
IC: P(75 mg/m 2)5 Fu(1000 mg/m2 for 4 days)-2 cycles +
CRT :65 Gy in 30# with cisplatin 100 mg/m2 on day 1 & 29)
Control arm: IC: cisplatin (100 mg/m2) 5 FU(1000 mg/m2/day)-5 days
CRT: 70-74 Gy with weekly carboplatin AUC 1.5
Control arm: IC:3 cisplatin100 m g/m2 5-FU1000 mg/m2-5 days-3 cycles
CRT: 70 gy IN 35# Cisplatin100 mg/m2 on day 1, 22, 43
IC: Paclitaxel/carbo platin weekly × 6 followed by
CRT: paclitaxel, 5-FU, hydroxyurea and twice daily radiation therapy every other week
IC: caboplatin/pa clitaxel-2 cycles
CRT: 70 in 35f with Concurrent Weekly paclitaxel Adjuvant chemo(2 cycles of carbo/taxol) + neck dissection in N2/N3 patients
IC: Cisplatin 100 mg/m2, 5 FU 1000 mg/m2 5 days-2 cycles
CRT: 72 Gy + cisplatin 100 mg/m2 day 1, 22, 43
Response IC: 78%(overall) IC: 76%(overall) IC: 64% (overall) IC: 68%(overall) IC: 87%(overall) IC:89%(over all) IC: 76%(overall)
  CRT: 85%(CR) CRT: 79%(CR)   CRT: 78% (CR) CRT:82% (CR) CRT:90% (CR) CRT:54% histological CR
Overall survival (OS), disease free survival (DFS) 65%(3 YR OS) 63% (2 YR OS) 48% (3 YR OS) 61.5% (2 YR OS) 70% (3 YR OS) 70% (3 YR OS) 64%(3 YR OS)
  75%(3 YR DFS) 68% (2 YR DFS)    80% (3 YR DFS)   
Logo-regionalcontrol (LRC) 91% in complete responders at 3 yrs 71% at 2 yrs 62% NR 94% (2 YR LRC) 82% at 3 YRS NR
Metastasi s-free survival 89% AT 3 yrs 91% at 2 yrs 91% NR 93% AT 2 YRS 81% ay 3 YRS NR
Toxicity-Acute (AC), Late (LT) Gr3/4 only IC: neutropenia 10%, mucositis 5%
CRT: 75% skin, 70%mucositis, dysphagia 63%
Late: 24%
IC: neutropenia 5%, n&v 3%
CRT: mucositis 60%, dysphagia 72%;
Late: 8%
IC: neutropenia 56%, mucositis 27%
CRT: mucositis38%, dysphagia 24%
IC: neutropenia 36%, mucositis(gr2-4) 53%
CRT: 4 toxic deaths
IC:36%neutropenia
CRT: 76% mucositis, 61% skin
CRT: 98%mucositis
Late: 24% Treatment mortality: 4%
IC: 29% grade4
CRT:19% grade4 Haematological
No of patients 41 145 246 193 69 53 59
Cancer site/staging All Tonsil
All stage 4
Oropharynx 54%
Stage4 60%
Oropharynx 53%
Stage 4 81%
Oropharynx 35%
Stage 4 83%
Oropharynx 44%
Stage 4 96%
All Oropharynx
Stage 4 65%
Oropharynx 62%tongue base
Stage 4 58%